MENU
SEP 17, 2020 3:30 PM PDT

Repurposing in COVID-19: Can we identify new antivirals

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Professor of Pathology and Laboratory Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania
    BIOGRAPHY

Abstract

There are an urgent need for antivirals to treat the newly emerged SARS-CoV-2. We set out to develop cell-based screens to repurpose existing drugs for use against SARS-CoV-2. Our goal was to identify both direct-acting and host-targeted antivirals. We have screened an in-house repurposing library of ~3,000 drugs in three distinct cell types permissive to SARS-CoV-2 infection: monkey kidney cells (Vero), human hepatocytes (Huh7.5) and human lung epithelial cells (Calu-3). There were 6 actives in Vero, 33 in Huh7.5 and 88 in Calu-3, with little overlap. While direct-acting antivirals such as remdesivir are active in all three cell types, we found few antivirals that were broadly active suggesting that the host dependencies are distinct in different cell types. Indeed, exploring entry pathways  revealed that in in lung epithelial Calu-3 cells entry is pH-independent and cathepsin-independent but requires TMPRSS2,. In contrast entry in Vero and Huh7.5 cells requires low pH and triggering by acid-dependent cathepsin proteases and is independent of TMPRSS2. Moreover, we found 9 drugs are antiviral in both hepatocytes and lung cells, 7 of which have been tested in humans, and 3 are FDA approved including Cyclosporine which we found is targeting Cyclophilin rather than Calcineurin for its antiviral activity revealing essential host targets that have the potential for rapid clinical implementation Specifically, I will discuss antiviral screening strategies and validation paradigms and discuss the implications of the cell type specificity. In addition, I will discuss some of our antivirals and mechanisms by which they function to block SARS-CoV-2 infection.

Learning Objectives:

1. Strategies for antiviral screening

2. Importance of cell types in antiviral discovery

3. Cellular dependencies of SARS-CoV-2 in the lung epithelium


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 14, 2021 7:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
MAR 16, 2021 10:00 AM PDT
C.E. CREDITS
MAR 16, 2021 10:00 AM PDT
Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
FEB 24, 2021 10:00 AM PST
C.E. CREDITS
FEB 24, 2021 10:00 AM PST
DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
APR 19, 2021 8:00 AM PDT
C.E. CREDITS
APR 19, 2021 8:00 AM PDT
Date: Apri 19, 2021 Time: 8:00am PDT, 5:00pm CEST Since the inception of modern biological research, BioSafety has evolved into a critical consideration in Good Laboratory Practices (GLP). Wi...
Loading Comments...
Show Resources